<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84869496414</prism:url><dc:identifier>SCOPUS_ID:84869496414</dc:identifier><eid>2-s2.0-84869496414</eid><pubmed-id>22795264</pubmed-id><pii>S0959804912005023</pii><prism:doi>10.1016/j.ejca.2012.06.011</prism:doi><dc:title>Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>12</citedby-count><prism:publicationName>European Journal of Cancer</prism:publicationName><source-id>29761</source-id><prism:issn>09598049 18790852</prism:issn><prism:volume>48</prism:volume><prism:issueIdentifier>18</prism:issueIdentifier><prism:startingPage>3378</prism:startingPage><prism:endingPage>3385</prism:endingPage><prism:pageRange>3378-3385</prism:pageRange><prism:coverDate>2012-12-01</prism:coverDate><openaccess>0</openaccess><openaccessFlag>false</openaccessFlag><dc:creator><author seq="1" auid="36992707400"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992707400</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng">
<ce:para>Introduction: The excision repair cross-complementing 1 (ERCC1) protein is an extensively investigated molecular marker because it may decrease sensitivity to platinum-based chemotherapy. Low ERCC1 expression has already been correlated with better treatment efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy. However, the data on a prognostic and/or predictive value of ERCC1 in small-cell lung cancer (SCLC) are still very limited. Methods: This retrospective pilot study evaluated the impact of ERCC1 expression levels on response to first-line platinum-based chemotherapy with or without radiotherapy and survival outcomes of 77 SCLC patients. ERCC1 protein expression was determined immunohistochemically in primary tumour tissue. Results: ERCC1 protein expression was positive in 40/77 (51.9%) of our patients. No significant association was found between ERCC1 protein expression and response rate to first-line platinum-based chemotherapy, progression-free survival (PFS), or overall survival (OS), either in the overall population or in patients stratified by disease stage. Conclusions: In our limited group of 77 SCLC patients, ERCC1 protein expression was not found to correlate with either response rate to platinum-based chemotherapy or survival outcomes. Multi-centric prospective trials using a validated method of ERCC1 determination are mandatory in order to obtain a definitive answer on the predictive value of ERCC1 in SCLC. © 2012 Elsevier Ltd. All rights reserved.</ce:para>
</abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84869496414" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84869496414&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84869496414&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"><affilname>University Clinic Maribor</affilname><affiliation-city>Maribor</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="36992707400"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992707400</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="2" auid="23976089500"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23976089500</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="3" auid="7003295818"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003295818</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="4" auid="36992456700"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovčariček T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992456700</author-url><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"/></author><author seq="5" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="6" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>ERCC1 protein expression</author-keyword><author-keyword>Platinum-based chemotherapy</author-keyword><author-keyword>Response to therapy</author-keyword><author-keyword>Small-cell lung cancer</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="1306" abbrev="BIOC">Cancer Research</subject-area><subject-area code="2730" abbrev="MEDI">Oncology</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2017-12-09T19:01:21.170Z</xocs:funding-addon-generated-timestamp></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="27" month="07" timestamp="2014-07-27T20:55:55.000055+01:00" year="2014"/><ait:date-sort day="01" month="12" year="2012"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2013 Elsevier B.V., All rights reserved.</copyright><copyright type="Medline Descriptors">MEDLINE® is the source for the MeSH terms of this document.</copyright><itemidlist>
<ce:pii>S0959804912005023</ce:pii>
<ce:doi>10.1016/j.ejca.2012.06.011</ce:doi>
<itemid idtype="PUI">52108199</itemid>
<itemid idtype="EMBASE">2012680083</itemid>
<itemid idtype="CABS">2012356582</itemid>
<itemid idtype="MOSYEA">2012131958</itemid>
<itemid idtype="BSTEIN">2012156438</itemid>
<itemid idtype="MEDL">22795264</itemid>
<itemid idtype="SCP">84869496414</itemid>
<itemid idtype="SGR">84869496414</itemid>
</itemidlist><history>
<date-created day="12" month="07" year="2012"/>
</history><dbcollection>EMBASE</dbcollection><dbcollection>CABS</dbcollection><dbcollection>MOSYEA</dbcollection><dbcollection>BSTEIN</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords>
<author-keyword>ERCC1 protein expression</author-keyword>
<author-keyword>Platinum-based chemotherapy</author-keyword>
<author-keyword>Response to therapy</author-keyword>
<author-keyword>Small-cell lung cancer</author-keyword>
</author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy</titletext></citation-title><author-group><author auid="36992707400" seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name>
<ce:initials>E.</ce:initials>
<ce:indexed-name>Sodja E.</ce:indexed-name>
<ce:surname>Sodja</ce:surname>
<ce:given-name>Eva</ce:given-name>
</preferred-name></author><author auid="23976089500" seq="2"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname><ce:given-name>Lea</ce:given-name><preferred-name>
<ce:initials>L.</ce:initials>
<ce:indexed-name>Knez L.</ce:indexed-name>
<ce:surname>Knez</ce:surname>
<ce:given-name>Lea</ce:given-name>
</preferred-name></author><author auid="7003295818" seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name>
<ce:initials>I.</ce:initials>
<ce:indexed-name>Kern I.</ce:indexed-name>
<ce:surname>Kern</ce:surname>
<ce:given-name>Izidor</ce:given-name>
</preferred-name></author><author auid="7004393140" seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Cufer T.</ce:indexed-name>
<ce:surname>Cufer</ce:surname>
<ce:given-name>Tanja</ce:given-name>
</preferred-name></author><affiliation afid="60078312" country="svn"><organization>University Clinic Golnik</organization><address-part>Golnik 36</address-part><city-group>4204 Golnik</city-group><country>Slovenia</country></affiliation></author-group><author-group><author auid="36992456700" seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovčariček</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Ovčariček T.</ce:indexed-name>
<ce:surname>Ovčariček</ce:surname>
<ce:given-name>Tanja</ce:given-name>
</preferred-name></author><affiliation afid="112789909" country="svn"><organization>University Clinic Maribor</organization><city-group>Maribor</city-group><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name>
<ce:initials>A.</ce:initials>
<ce:indexed-name>Sadikov A.</ce:indexed-name>
<ce:surname>Sadikov</ce:surname>
<ce:given-name>Aleksander</ce:given-name>
</preferred-name></author><affiliation afid="60031106" country="svn"><organization>University of Ljubljana</organization><organization>Faculty of Computer and Information Science</organization><city-group>Ljubljana</city-group><country>Slovenia</country></affiliation></author-group><correspondence><person>
<ce:initials>E.</ce:initials>
<ce:indexed-name>Sodja E.</ce:indexed-name>
<ce:surname>Sodja</ce:surname>
</person><affiliation country="svn"><organization>University Clinic Golnik</organization><address-part>Golnik 36</address-part><city-group>4204 Golnik</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng">
<ce:para>Introduction: The excision repair cross-complementing 1 (ERCC1) protein is an extensively investigated molecular marker because it may decrease sensitivity to platinum-based chemotherapy. Low ERCC1 expression has already been correlated with better treatment efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy. However, the data on a prognostic and/or predictive value of ERCC1 in small-cell lung cancer (SCLC) are still very limited. Methods: This retrospective pilot study evaluated the impact of ERCC1 expression levels on response to first-line platinum-based chemotherapy with or without radiotherapy and survival outcomes of 77 SCLC patients. ERCC1 protein expression was determined immunohistochemically in primary tumour tissue. Results: ERCC1 protein expression was positive in 40/77 (51.9%) of our patients. No significant association was found between ERCC1 protein expression and response rate to first-line platinum-based chemotherapy, progression-free survival (PFS), or overall survival (OS), either in the overall population or in patients stratified by disease stage. Conclusions: In our limited group of 77 SCLC patients, ERCC1 protein expression was not found to correlate with either response rate to platinum-based chemotherapy or survival outcomes. Multi-centric prospective trials using a validated method of ERCC1 determination are mandatory in order to obtain a definitive answer on the predictive value of ERCC1 in SCLC. © 2012 Elsevier Ltd. All rights reserved.</ce:para>
</abstract></abstracts><source country="gbr" srcid="29761" type="j"><sourcetitle>European Journal of Cancer</sourcetitle><sourcetitle-abbrev>Eur. J. Cancer</sourcetitle-abbrev><issn type="print">09598049</issn><issn type="electronic">18790852</issn><codencode>EJCAE</codencode><volisspag>
<voliss issue="18" volume="48"/>
<pagerange first="3378" last="3385"/>
</volisspag><publicationyear first="2012"/><publicationdate>
<year>2012</year>
<month>12</month>
<date-text xfab-added="true">December 2012</date-text></publicationdate></source><enhancement><classificationgroup>
<classifications type="ASJC">
<classification>1306</classification>
<classification>2730</classification>
</classifications><classifications type="SUBJABBR"><classification>BIOC</classification><classification>MEDI</classification></classifications>
<classifications type="CABSCLASS">
<classification> <classification-code>87.4.1</classification-code> <classification-description>CANCER RESEARCH; TREATMENT; Chemotherapy</classification-description> </classification>
<classification> <classification-code>87.5.7</classification-code> <classification-description>CANCER RESEARCH; CLINICAL INVESTIGATIONS BY ORGAN SITE; Lung</classification-description> </classification>
</classifications>
<classifications type="EMCLASS">
<classification> <classification-code>16.13</classification-code> <classification-description>Cancer; RESPIRATORY SYSTEM</classification-description> </classification>
<classification> <classification-code>16.4.1</classification-code> <classification-description>Cancer; TREATMENT AND PATIENT MANAGEMENT; Chemotherapy</classification-description> </classification>
<classification> <classification-code>29.4</classification-code> <classification-description>Clinical and Experimental Biochemistry; MOLECULAR BIOLOGY</classification-description> </classification>
<classification> <classification-code>29.5</classification-code> <classification-description>Clinical and Experimental Biochemistry; PROTEIN STRUCTURE AND FUNCTION</classification-description> </classification>
<classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification>
</classifications>
</classificationgroup><chemicalgroup>
<chemicals source="esbd">
<chemical>
<chemical-name>cisplatin</chemical-name>
<cas-registry-number>15663-27-1</cas-registry-number>
<cas-registry-number>26035-31-4</cas-registry-number>
<cas-registry-number>96081-74-2</cas-registry-number>
</chemical>
<chemical>
<chemical-name>cyclophosphamide</chemical-name>
<cas-registry-number>50-18-0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>epirubicin</chemical-name>
<cas-registry-number>56390-09-1</cas-registry-number>
<cas-registry-number>56420-45-2</cas-registry-number>
</chemical>
<chemical>
<chemical-name>etoposide</chemical-name>
<cas-registry-number>33419-42-0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>vincristine</chemical-name>
<cas-registry-number>57-22-7</cas-registry-number>
</chemical>
</chemicals>
<chemicals source="nlm">
<chemical>
<chemical-name>Antineoplastic Agents, Alkylating</chemical-name>
<cas-registry-number>0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Cisplatin</chemical-name>
<cas-registry-number>15663-27-1</cas-registry-number>
</chemical>
<chemical>
<chemical-name>DNA, Neoplasm</chemical-name>
<cas-registry-number>0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>DNA-Binding Proteins</chemical-name>
<cas-registry-number>0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>ERCC1 protein, human</chemical-name>
<cas-registry-number>3.1.-</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Endonucleases</chemical-name>
<cas-registry-number>3.1.-</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Epirubicin</chemical-name>
<cas-registry-number>56420-45-2</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Etoposide</chemical-name>
<cas-registry-number>33419-42-0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Neoplasm Proteins</chemical-name>
<cas-registry-number>0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Topotecan</chemical-name>
<cas-registry-number>123948-87-8</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Vincristine</chemical-name>
<cas-registry-number>57-22-7</cas-registry-number>
</chemical>
</chemicals>
</chemicalgroup></enhancement></head><tail><bibliography refcount="35">
<reference id="1">
<ref-info>
<ref-title>
<ref-titletext>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">78049485263</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Ferlay J.</ce:indexed-name>
<ce:surname>Ferlay</ce:surname>
</author>
<author seq="2">
<ce:initials>H.R.</ce:initials>
<ce:indexed-name>Shin H.R.</ce:indexed-name>
<ce:surname>Shin</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Bray F.</ce:indexed-name>
<ce:surname>Bray</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int J Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="127"/>
<pagerange first="2893" last="2917"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917</ref-fulltext>
</reference>
<reference id="2">
<ref-info>
<ref-title>
<ref-titletext>Cancer statistics, 2010</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77955635233</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Jemal A.</ce:indexed-name>
<ce:surname>Jemal</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Siegel R.</ce:indexed-name>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Xu J.</ce:indexed-name>
<ce:surname>Xu</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Ward E.</ce:indexed-name>
<ce:surname>Ward</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J Clin</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="60"/>
<pagerange first="277" last="300"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300</ref-fulltext>
</reference>
<reference id="3">
<ref-info>
<ref-title>
<ref-titletext>Prognostic factors differ by tumor stage for small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">67649184760</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>N.R.</ce:initials>
<ce:indexed-name>Foster N.R.</ce:indexed-name>
<ce:surname>Foster</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:indexed-name>Mandrekar S.J.</ce:indexed-name>
<ce:surname>Mandrekar</ce:surname>
</author>
<author seq="3">
<ce:initials>S.E.</ce:initials>
<ce:indexed-name>Schild S.E.</ce:indexed-name>
<ce:surname>Schild</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="115"/>
<pagerange first="2721" last="2731"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>N.R. Foster, S.J. Mandrekar, and S.E. Schild Prognostic factors differ by tumor stage for small cell lung cancer Cancer 115 2009 2721 2731</ref-fulltext>
</reference>
<reference id="4">
<ref-info>
<ref-title>
<ref-titletext>New advances in the second-line treatment of small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">73349141727</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:indexed-name>Hurwitz J.L.</ce:indexed-name>
<ce:surname>Hurwitz</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:indexed-name>McCoy F.</ce:indexed-name>
<ce:surname>McCoy</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Scullin P.</ce:indexed-name>
<ce:surname>Scullin</ce:surname>
</author>
<author seq="4">
<ce:initials>D.A.</ce:initials>
<ce:indexed-name>Fennell D.A.</ce:indexed-name>
<ce:surname>Fennell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncologist</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="14"/>
<pagerange first="986" last="994"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>J.L. Hurwitz, F. McCoy, P. Scullin, and D.A. Fennell New advances in the second-line treatment of small cell lung cancer Oncologist 14 2009 986 994</ref-fulltext>
</reference>
<reference id="5">
<ref-info>
<ref-title>
<ref-titletext>Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-analysis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">80155141268</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:indexed-name>Roth J.A.</ce:indexed-name>
<ce:surname>Roth</ce:surname>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:indexed-name>Carlson J.J.</ce:indexed-name>
<ce:surname>Carlson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="12"/>
<pagerange first="393" last="401"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>J.A. Roth, and J.J. Carlson Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-analysis Clin Lung Cancer 12 2011 393 401</ref-fulltext>
</reference>
<reference id="6">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: A meta-analysis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">84864280988</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Jiang J.</ce:indexed-name>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:indexed-name>Liang X.</ce:indexed-name>
<ce:surname>Liang</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:indexed-name>Zhou X.</ce:indexed-name>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Huang R.</ce:indexed-name>
<ce:surname>Huang</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:indexed-name>Chu Z.</ce:indexed-name>
<ce:surname>Chu</ce:surname>
</author>
<author seq="6">
<ce:initials>Q.</ce:initials>
<ce:indexed-name>Zhan Q.</ce:indexed-name>
<ce:surname>Zhan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol Biol Rep</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-text>PMID: 22302397</ref-text>
</ref-info>
<ref-fulltext>J. Jiang, X. Liang, X. Zhou, R. Huang, Z. Chu, and Q. Zhan ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: A meta-analysis Mol Biol Rep 2012 PMID: 22302397</ref-fulltext>
</reference>
<reference id="7">
<ref-info>
<ref-title>
<ref-titletext>Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: A meta-analysis of published studies and recommendations</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">80054107639</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:indexed-name>Hubner R.A.</ce:indexed-name>
<ce:surname>Hubner</ce:surname>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:indexed-name>Riley R.D.</ce:indexed-name>
<ce:surname>Riley</ce:surname>
</author>
<author seq="3">
<ce:initials>L.J.</ce:initials>
<ce:indexed-name>Billingham L.J.</ce:indexed-name>
<ce:surname>Billingham</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Popat S.</ce:indexed-name>
<ce:surname>Popat</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>PLoS One</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="6"/>
<pagerange first="25164"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>R.A. Hubner, R.D. Riley, L.J. Billingham, and S. Popat Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: A meta-analysis of published studies and recommendations PLoS One 6 2011 e25164</ref-fulltext>
</reference>
<reference id="8">
<ref-info>
<ref-title>
<ref-titletext>Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis- acetoammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0033566758</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:indexed-name>Reardon J.T.</ce:indexed-name>
<ce:surname>Reardon</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Vaisman A.</ce:indexed-name>
<ce:surname>Vaisman</ce:surname>
</author>
<author seq="3">
<ce:initials>S.G.</ce:initials>
<ce:indexed-name>Chaney S.G.</ce:indexed-name>
<ce:surname>Chaney</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Sancar A.</ce:indexed-name>
<ce:surname>Sancar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Research</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<ref-volisspag>
<voliss issue="16" volume="59"/>
<pagerange first="3968" last="3971"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>J.T. Reardon, A. Vaisman, S.G. Chaney, and A. Sancar Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res 59 1999 3968 3971 (Pubitemid 29393563)</ref-fulltext>
</reference>
<reference id="9">
<ref-info>
<ref-title>
<ref-titletext>DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">33748435058</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:indexed-name>Olaussen K.A.</ce:indexed-name>
<ce:surname>Olaussen</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Dunant A.</ce:indexed-name>
<ce:surname>Dunant</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Fouret P.</ce:indexed-name>
<ce:surname>Fouret</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Brambilla E.</ce:indexed-name>
<ce:surname>Brambilla</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Andre F.</ce:indexed-name>
<ce:surname>Andre</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Haddad V.</ce:indexed-name>
<ce:surname>Haddad</ce:surname>
</author>
<author seq="7">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Taranchon E.</ce:indexed-name>
<ce:surname>Taranchon</ce:surname>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Filipits M.</ce:indexed-name>
<ce:surname>Filipits</ce:surname>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Pirker R.</ce:indexed-name>
<ce:surname>Pirker</ce:surname>
</author>
<author seq="10">
<ce:initials>H.H.</ce:initials>
<ce:indexed-name>Popper H.H.</ce:indexed-name>
<ce:surname>Popper</ce:surname>
</author>
<author seq="11">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Stahel R.</ce:indexed-name>
<ce:surname>Stahel</ce:surname>
</author>
<author seq="12">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Sabatier L.</ce:indexed-name>
<ce:surname>Sabatier</ce:surname>
</author>
<author seq="13">
<ce:initials>J.-P.</ce:initials>
<ce:indexed-name>Pignon J.-P.</ce:indexed-name>
<ce:surname>Pignon</ce:surname>
</author>
<author seq="14">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Tursz T.</ce:indexed-name>
<ce:surname>Tursz</ce:surname>
</author>
<author seq="15">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Le Chevalier T.</ce:indexed-name>
<ce:surname>Le Chevalier</ce:surname>
</author>
<author seq="16">
<ce:initials>J.-C.</ce:initials>
<ce:indexed-name>Soria J.-C.</ce:indexed-name>
<ce:surname>Soria</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>New England Journal of Medicine</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-volisspag>
<voliss issue="10" volume="355"/>
<pagerange first="983" last="991"/>
</ref-volisspag>
<ref-website>
<ce:e-address type="url">http://content.nejm.org/cgi/reprint/355/10/983.pdf</ce:e-address>
</ref-website>
<ref-text>DOI 10.1056/NEJMoa060570</ref-text>
</ref-info>
<ref-fulltext>K.A. Olaussen, A. Dunant, and P. Fouret For the IALT bio investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991 (Pubitemid 44343542)</ref-fulltext>
</reference>
<reference id="10">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79251503287</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Bepler G.</ce:indexed-name>
<ce:surname>Bepler</ce:surname>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:indexed-name>Olaussen K.A.</ce:indexed-name>
<ce:surname>Olaussen</ce:surname>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:indexed-name>Vataire A.L.</ce:indexed-name>
<ce:surname>Vataire</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Am J Pathol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="178"/>
<pagerange first="69" last="78"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>G. Bepler, K.A. Olaussen, and A.L. Vataire ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis Am J Pathol 178 2011 69 78</ref-fulltext>
</reference>
<reference id="11">
<ref-info>
<ref-title>
<ref-titletext>Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">34447573875</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Cobo M.</ce:indexed-name>
<ce:surname>Cobo</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Isla D.</ce:indexed-name>
<ce:surname>Isla</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Massuti B.</ce:indexed-name>
<ce:surname>Massuti</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Montes A.</ce:indexed-name>
<ce:surname>Montes</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:indexed-name>Sanchez J.M.</ce:indexed-name>
<ce:surname>Sanchez</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Provencio M.</ce:indexed-name>
<ce:surname>Provencio</ce:surname>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Vinolas N.</ce:indexed-name>
<ce:surname>Vinolas</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Paz-Ares L.</ce:indexed-name>
<ce:surname>Paz-Ares</ce:surname>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Lopez-Vivanco G.</ce:indexed-name>
<ce:surname>Lopez-Vivanco</ce:surname>
</author>
<author seq="10">
<ce:initials>M.A.</ce:initials>
<ce:indexed-name>Munoz M.A.</ce:indexed-name>
<ce:surname>Munoz</ce:surname>
</author>
<author seq="11">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Felip E.</ce:indexed-name>
<ce:surname>Felip</ce:surname>
</author>
<author seq="12">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Alberola V.</ce:indexed-name>
<ce:surname>Alberola</ce:surname>
</author>
<author seq="13">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Camps C.</ce:indexed-name>
<ce:surname>Camps</ce:surname>
</author>
<author seq="14">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Domine M.</ce:indexed-name>
<ce:surname>Domine</ce:surname>
</author>
<author seq="15">
<ce:initials>J.J.</ce:initials>
<ce:indexed-name>Sanchez J.J.</ce:indexed-name>
<ce:surname>Sanchez</ce:surname>
</author>
<author seq="16">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Sanchez-Ronco M.</ce:indexed-name>
<ce:surname>Sanchez-Ronco</ce:surname>
</author>
<author seq="17">
<ce:initials>K.</ce:initials>
<ce:indexed-name>Danenberg K.</ce:indexed-name>
<ce:surname>Danenberg</ce:surname>
</author>
<author seq="18">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Taron M.</ce:indexed-name>
<ce:surname>Taron</ce:surname>
</author>
<author seq="19">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Gandara D.</ce:indexed-name>
<ce:surname>Gandara</ce:surname>
</author>
<author seq="20">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Rosell R.</ce:indexed-name>
<ce:surname>Rosell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="19" volume="25"/>
<pagerange first="2747" last="2754"/>
</ref-volisspag>
<ref-text>DOI 10.1200/JCO.2006.09.7915</ref-text>
</ref-info>
<ref-fulltext>M. Cobo, D. Isla, and B. Massuti Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer J Clin Oncol 25 2007 2747 2754 (Pubitemid 47123183)</ref-fulltext>
</reference>
<reference id="12">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77956124352</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:indexed-name>Vilmar A.C.</ce:indexed-name>
<ce:surname>Vilmar</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Santoni-Rugiu E.</ce:indexed-name>
<ce:surname>Santoni-Rugiu</ce:surname>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:indexed-name>Sorensen J.B.</ce:indexed-name>
<ce:surname>Sorensen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="21"/>
<pagerange first="1817" last="1824"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>A.C. Vilmar, E. Santoni-Rugiu, and J.B. Sorensen ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial Ann Oncol 21 2010 1817 1824</ref-fulltext>
</reference>
<reference id="13">
<ref-info>
<ref-title>
<ref-titletext>Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">61449247252</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Ota S.</ce:indexed-name>
<ce:surname>Ota</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Ishii G.</ce:indexed-name>
<ce:surname>Ishii</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:indexed-name>Goto K.</ce:indexed-name>
<ce:surname>Goto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="64"/>
<pagerange first="98" last="194"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>S. Ota, G. Ishii, and K. Goto Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy Lung cancer 64 2009 98 194</ref-fulltext>
</reference>
<reference id="14">
<ref-info>
<ref-title>
<ref-titletext>Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">70349331482</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Holm B.</ce:indexed-name>
<ce:surname>Holm</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Mellemgaard A.</ce:indexed-name>
<ce:surname>Mellemgaard</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Skov T.</ce:indexed-name>
<ce:surname>Skov</ce:surname>
</author>
<author seq="4">
<ce:initials>B.G.</ce:initials>
<ce:indexed-name>Skov B.G.</ce:indexed-name>
<ce:surname>Skov</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="27"/>
<pagerange first="4254" last="4259"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>B. Holm, A. Mellemgaard, T. Skov, and B.G. Skov Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine J Clin Oncol 27 2009 4254 4259</ref-fulltext>
</reference>
<reference id="15">
<ref-info>
<ref-title>
<ref-titletext>Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77956894860</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:indexed-name>Wang X.</ce:indexed-name>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Zhao J.</ce:indexed-name>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Yang L.</ce:indexed-name>
<ce:surname>Yang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Med Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="27"/>
<pagerange first="484" last="490"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>X. Wang, J. Zhao, and L. Yang Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer Med Oncol 27 2010 484 490</ref-fulltext>
</reference>
<reference id="16">
<ref-info>
<ref-title>
<ref-titletext>High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">78649302696</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Ren S.</ce:indexed-name>
<ce:surname>Ren</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Zhou S.</ce:indexed-name>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Zhang L.</ce:indexed-name>
<ce:surname>Zhang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Invest</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="28"/>
<pagerange first="1078" last="1083"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>S. Ren, S. Zhou, and L. Zhang High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients Cancer Invest 28 2010 1078 1083</ref-fulltext>
</reference>
<reference id="17">
<ref-info>
<ref-title>
<ref-titletext>Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">76649129015</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>X.Q.</ce:initials>
<ce:indexed-name>Li X.Q.</ce:indexed-name>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Li J.</ce:indexed-name>
<ce:surname>Li</ce:surname>
</author>
<author seq="3">
<ce:initials>S.B.</ce:initials>
<ce:indexed-name>Shi S.B.</ce:indexed-name>
<ce:surname>Shi</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Chen P.</ce:indexed-name>
<ce:surname>Chen</ce:surname>
</author>
<author seq="5">
<ce:initials>L.C.</ce:initials>
<ce:indexed-name>Yu L.C.</ce:indexed-name>
<ce:surname>Yu</ce:surname>
</author>
<author seq="6">
<ce:initials>Q.L.</ce:initials>
<ce:indexed-name>Bao Q.L.</ce:indexed-name>
<ce:surname>Bao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int J Biol Markers</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="24"/>
<pagerange first="230" last="237"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>X.Q. Li, J. Li, S.B. Shi, P. Chen, L.C. Yu, and Q.L. Bao Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy Int J Biol Markers 24 2009 230 237</ref-fulltext>
</reference>
<reference id="18">
<ref-info>
<ref-title>
<ref-titletext>Predictive value of multidrug resistance proteins, topoisomerase II and ERCC1 in small cell lung cancer: A systematic review</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79955466333</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Knez L.</ce:indexed-name>
<ce:surname>Knez</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Sodja E.</ce:indexed-name>
<ce:surname>Sodja</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:indexed-name>Kern I.</ce:indexed-name>
<ce:surname>Kern</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Kosnik M.</ce:indexed-name>
<ce:surname>Košnik</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Cufer T.</ce:indexed-name>
<ce:surname>Cufer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="73"/>
<pagerange first="271" last="279"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>L. Knez, E. Sodja, I. Kern, M. Košnik, and T. Cufer Predictive value of multidrug resistance proteins, topoisomerase II and ERCC1 in small cell lung cancer: A systematic review Lung cancer 73 2011 271 279</ref-fulltext>
</reference>
<reference id="19">
<ref-info>
<ref-title>
<ref-titletext>Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">37549056534</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>H.W.</ce:initials>
<ce:indexed-name>Lee H.W.</ce:indexed-name>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>J.H.</ce:initials>
<ce:indexed-name>Han J.H.</ce:indexed-name>
<ce:surname>Han</ce:surname>
</author>
<author seq="3">
<ce:initials>J.H.</ce:initials>
<ce:indexed-name>Kim J.H.</ce:indexed-name>
<ce:surname>Kim</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-volisspag>
<voliss volume="59"/>
<pagerange first="95" last="104"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>H.W. Lee, J.H. Han, and J.H. Kim Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer Lung cancer 59 2008 95 104</ref-fulltext>
</reference>
<reference id="20">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 and small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">78149458450</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Rossi G.</ce:indexed-name>
<ce:surname>Rossi</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Nannini N.</ce:indexed-name>
<ce:surname>Nannini</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Tiseo M.</ce:indexed-name>
<ce:surname>Tiseo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Thorac Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="5"/>
<pagerange first="1876" last="1877"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>G. Rossi, N. Nannini, and M. Tiseo ERCC1 and small cell lung cancer J Thorac Oncol 5 2010 1876 1877</ref-fulltext>
</reference>
<reference id="21">
<ref-info>
<ref-title>
<ref-titletext>Excision repair cross complementing-1 and topoisomerase IIα gene expression in small-cell lung cancer patients treated with platinum and etoposide: A retrospective study</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">44649107673</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Ceppi P.</ce:indexed-name>
<ce:surname>Ceppi</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Longo M.</ce:indexed-name>
<ce:surname>Longo</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Volante M.</ce:indexed-name>
<ce:surname>Volante</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Novello S.</ce:indexed-name>
<ce:surname>Novello</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Cappia S.</ce:indexed-name>
<ce:surname>Cappia</ce:surname>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Bacillo E.</ce:indexed-name>
<ce:surname>Bacillo</ce:surname>
</author>
<author seq="7">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Selvaggi G.</ce:indexed-name>
<ce:surname>Selvaggi</ce:surname>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Saviozzi S.</ce:indexed-name>
<ce:surname>Saviozzi</ce:surname>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Calogero R.</ce:indexed-name>
<ce:surname>Calogero</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Papotti M.</ce:indexed-name>
<ce:surname>Papotti</ce:surname>
</author>
<author seq="11">
<ce:initials>G.V.</ce:initials>
<ce:indexed-name>Scagliotti G.V.</ce:indexed-name>
<ce:surname>Scagliotti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Thoracic Oncology</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<ref-volisspag>
<voliss issue="6" volume="3"/>
<pagerange first="583" last="589"/>
</ref-volisspag>
<ref-text>DOI 10.1097/JTO.0b013e3181734f24, PII 0124389420080600000005</ref-text>
</ref-info>
<ref-fulltext>P. Ceppi, M. Longo, and M. Volante Excision repair cross complementing-1 and topoisomerase IIα gene expression in small-cell lung cancer patients treated with platinum and etoposide J Thorac Oncol 3 2008 583 589 (Pubitemid 351787300)</ref-fulltext>
</reference>
<reference id="22">
<ref-info>
<ref-title>
<ref-titletext>Expression of breast cancer resistance protein is associated with poor clinical outcome in patients with small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">67349169090</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>Y.H.</ce:initials>
<ce:indexed-name>Kim Y.H.</ce:indexed-name>
<ce:surname>Kim</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Ishii G.</ce:indexed-name>
<ce:surname>Ishii</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:indexed-name>Goto K.</ce:indexed-name>
<ce:surname>Goto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="65"/>
<pagerange first="105" last="111"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Y.H. Kim, G. Ishii, and K. Goto Expression of breast cancer resistance protein is associated with poor clinical outcome in patients with small-cell lung cancer Lung cancer 65 2009 105 111</ref-fulltext>
</reference>
<reference id="23">
<ref-info>
<ref-title>
<ref-titletext>N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77953394135</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Batus M.</ce:indexed-name>
<ce:surname>Batus</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Myint R.</ce:indexed-name>
<ce:surname>Myint</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Coon J.</ce:indexed-name>
<ce:surname>Coon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss issue="SUPPL." volume="27"/>
</ref-volisspag>
<ref-text>Abstract 221579</ref-text>
</ref-info>
<ref-fulltext>M. Batus, R. Myint, and J. Coon N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets J Clin Oncol 27 2009 Suppl. Abstract 221579</ref-fulltext>
</reference>
<reference id="24">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 expression and survival in small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77953426518</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Hennemann M.</ce:indexed-name>
<ce:surname>Hennemann</ce:surname>
</author>
<author seq="2">
<ce:initials>M.H.</ce:initials>
<ce:indexed-name>Sostruznik M.H.</ce:indexed-name>
<ce:surname>Sostruznik</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:indexed-name>Gaiger A.M.</ce:indexed-name>
<ce:surname>Gaiger</ce:surname>
</author>
<author seq="4">
<ce:initials>C.H.</ce:initials>
<ce:indexed-name>Barrios C.H.</ce:indexed-name>
<ce:surname>Barrios</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss issue="SUPPL." volume="27"/>
</ref-volisspag>
<ref-text>Abstract 19080</ref-text>
</ref-info>
<ref-fulltext>M. Hennemann, M.H. Sostruznik, A.M. Gaiger, and C.H. Barrios ERCC1 expression and survival in small cell lung cancer J Clin Oncol 27 2009 Suppl. Abstract 19080</ref-fulltext>
</reference>
<reference id="25">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77950996012</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>B.G.</ce:initials>
<ce:indexed-name>Skov B.G.</ce:indexed-name>
<ce:surname>Skov</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Holm B.</ce:indexed-name>
<ce:surname>Holm</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Erreboe A.</ce:indexed-name>
<ce:surname>Erreboe</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Skov T.</ce:indexed-name>
<ce:surname>Skov</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Mellemgaard A.</ce:indexed-name>
<ce:surname>Mellemgaard</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Thorac Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="5"/>
<pagerange first="453" last="459"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>B.G. Skov, B. Holm, A. Erreboe, T. Skov, and A. Mellemgaard ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung J Thorac Oncol 5 2010 453 459</ref-fulltext>
</reference>
<reference id="26">
<ref-info>
<ref-title>
<ref-titletext>Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79953786810</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Rossman J.</ce:indexed-name>
<ce:surname>Rossman</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Reddy V.</ce:indexed-name>
<ce:surname>Reddy</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Cantor A.</ce:indexed-name>
<ce:surname>Cantor</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Miley D.</ce:indexed-name>
<ce:surname>Miley</ce:surname>
</author>
<author seq="5">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Robert F.</ce:indexed-name>
<ce:surname>Robert</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lung Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="72"/>
<pagerange first="219" last="223"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>J. Rossman, V. Reddy, A. Cantor, D. Miley, and F. Robert Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer Lung Cancer 72 2011 219 223</ref-fulltext>
</reference>
<reference id="27">
<ref-info>
<ref-title>
<ref-titletext>Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">84866181889</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>E.F.</ce:initials>
<ce:indexed-name>Smit E.F.</ce:indexed-name>
<ce:surname>Smit</ce:surname>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:indexed-name>Socinski M.A.</ce:indexed-name>
<ce:surname>Socinski</ce:surname>
</author>
<author seq="3">
<ce:initials>B.P.</ce:initials>
<ce:indexed-name>Mullaney B.P.</ce:indexed-name>
<ce:surname>Mullaney</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-text>in press</ref-text>
</ref-info>
<ref-fulltext>E.F. Smit, M.A. Socinski, and B.P. Mullaney Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer Ann Oncol 2011 in press</ref-fulltext>
</reference>
<reference id="28">
<ref-info>
<ref-title>
<ref-titletext>REporting recommendations for tumour MARKer prognostic studies (REMARK)</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">23644432019</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>L.M.</ce:initials>
<ce:indexed-name>McShane L.M.</ce:indexed-name>
<ce:surname>McShane</ce:surname>
</author>
<author seq="2">
<ce:initials>D.G.</ce:initials>
<ce:indexed-name>Altman D.G.</ce:indexed-name>
<ce:surname>Altman</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:indexed-name>Sauerbrei W.</ce:indexed-name>
<ce:surname>Sauerbrei</ce:surname>
</author>
<author seq="4">
<ce:initials>S.E.</ce:initials>
<ce:indexed-name>Taube S.E.</ce:indexed-name>
<ce:surname>Taube</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Gion M.</ce:indexed-name>
<ce:surname>Gion</ce:surname>
</author>
<author seq="6">
<ce:initials>G.M.</ce:initials>
<ce:indexed-name>Clark G.M.</ce:indexed-name>
<ce:surname>Clark</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>European Journal of Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<voliss issue="12" volume="41"/>
<pagerange first="1690" last="1696"/>
</ref-volisspag>
<ref-text>DOI 10.1016/j.ejca.2005.03.032, PII S0959804905004429</ref-text>
</ref-info>
<ref-fulltext>L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark REporting recommendations for tumour MARKer prognostic studies (REMARK) Eur J Cancer 41 2005 1690 1696 (Pubitemid 41132629)</ref-fulltext>
</reference>
<reference id="29">
<ref-info>
<ref-title>
<ref-titletext>Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">78149360164</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:indexed-name>Doll C.M.</ce:indexed-name>
<ce:surname>Doll</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Prystajecky M.</ce:indexed-name>
<ce:surname>Prystajecky</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Eliasziw M.</ce:indexed-name>
<ce:surname>Eliasziw</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Radiother Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="97"/>
<pagerange first="352" last="359"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>C.M. Doll, M. Prystajecky, and M. Eliasziw Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone Radiother Oncol 97 2010 352 359</ref-fulltext>
</reference>
<reference id="30">
<ref-info>
<ref-title>
<ref-titletext>Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">34447126864</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Handra-Luca A.</ce:indexed-name>
<ce:surname>Handra-Luca</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Hernandez J.</ce:indexed-name>
<ce:surname>Hernandez</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Mountzios G.</ce:indexed-name>
<ce:surname>Mountzios</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Taranchon E.</ce:indexed-name>
<ce:surname>Taranchon</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Lacau-St-Guily J.</ce:indexed-name>
<ce:surname>Lacau-St-Guily</ce:surname>
</author>
<author seq="6">
<ce:initials>J.-C.</ce:initials>
<ce:indexed-name>Soria J.-C.</ce:indexed-name>
<ce:surname>Soria</ce:surname>
</author>
<author seq="7">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Fouret P.</ce:indexed-name>
<ce:surname>Fouret</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clinical Cancer Research</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="13" volume="13"/>
<pagerange first="3855" last="3859"/>
</ref-volisspag>
<ref-website>
<ce:e-address type="url">http://clincancerres.aacrjournals.org/cgi/reprint/13/13/3855.pdf</ce:e-address>
</ref-website>
<ref-text>DOI 10.1158/1078-0432.CCR-07-0252</ref-text>
</ref-info>
<ref-fulltext>A. Handra-Luca, J. Hernandez, and G. Mountzios Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma Clin Cancer Res 13 2007 3855 3859 (Pubitemid 47037591)</ref-fulltext>
</reference>
<reference id="31">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">36849044583</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Smith S.</ce:indexed-name>
<ce:surname>Smith</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Su D.</ce:indexed-name>
<ce:surname>Su</ce:surname>
</author>
<author seq="3">
<ce:initials>I.A.</ce:initials>
<ce:indexed-name>Rigault De La Longrais I.A.</ce:indexed-name>
<ce:surname>Rigault De La Longrais</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Schwartz P.</ce:indexed-name>
<ce:surname>Schwartz</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Puopolo M.</ce:indexed-name>
<ce:surname>Puopolo</ce:surname>
</author>
<author seq="6">
<ce:initials>T.J.</ce:initials>
<ce:indexed-name>Rutherford T.J.</ce:indexed-name>
<ce:surname>Rutherford</ce:surname>
</author>
<author seq="7">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Mor G.</ce:indexed-name>
<ce:surname>Mor</ce:surname>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Yu H.</ce:indexed-name>
<ce:surname>Yu</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Katsaros D.</ce:indexed-name>
<ce:surname>Katsaros</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Clinical Oncology</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="33" volume="25"/>
<pagerange first="5172" last="5179"/>
</ref-volisspag>
<ref-website>
<ce:e-address type="url">http://jco.ascopubs.org/cgi/reprint/25/33/5172</ce:e-address>
</ref-website>
<ref-text>DOI 10.1200/JCO.2007.11.8547</ref-text>
</ref-info>
<ref-fulltext>S. Smith, D. Su, and I.A. Rigault de la Longrais ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy J Clin Oncol 25 2007 5172 5179 (Pubitemid 350232247)</ref-fulltext>
</reference>
<reference id="32">
<ref-info>
<ref-title>
<ref-titletext>ERCC1 and non-small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">34250333804</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:indexed-name>Niedernhofer L.J.</ce:indexed-name>
<ce:surname>Niedernhofer</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Bhagwat N.</ce:indexed-name>
<ce:surname>Bhagwat</ce:surname>
</author>
<author seq="3">
<ce:initials>R.D.</ce:initials>
<ce:indexed-name>Wood R.D.</ce:indexed-name>
<ce:surname>Wood</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss volume="356"/>
<pagerange first="2538" last="2540"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>L.J. Niedernhofer, N. Bhagwat, and R.D. Wood ERCC1 and non-small-cell lung cancer N Engl J Med 356 2007 2538 2540</ref-fulltext>
</reference>
<reference id="33">
<ref-info>
<ref-title>
<ref-titletext>Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">70149098012</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>N.R.</ce:initials>
<ce:indexed-name>Bhagwat N.R.</ce:indexed-name>
<ce:surname>Bhagwat</ce:surname>
</author>
<author seq="2">
<ce:initials>V.Y.</ce:initials>
<ce:indexed-name>Roginskaya V.Y.</ce:indexed-name>
<ce:surname>Roginskaya</ce:surname>
</author>
<author seq="3">
<ce:initials>M.B.</ce:initials>
<ce:indexed-name>Acquafondata M.B.</ce:indexed-name>
<ce:surname>Acquafondata</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Dhir R.</ce:indexed-name>
<ce:surname>Dhir</ce:surname>
</author>
<author seq="5">
<ce:initials>R.D.</ce:initials>
<ce:indexed-name>Wood R.D.</ce:indexed-name>
<ce:surname>Wood</ce:surname>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:indexed-name>Niedernhofer L.J.</ce:indexed-name>
<ce:surname>Niedernhofer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="69"/>
<pagerange first="6831" last="6838"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>N.R. Bhagwat, V.Y. Roginskaya, M.B. Acquafondata, R. Dhir, R.D. Wood, and L.J. Niedernhofer Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue Cancer Res 69 2009 6831 6838</ref-fulltext>
</reference>
<reference id="34">
<ref-info>
<ref-title>
<ref-titletext>ERCC1-specific immunostaining in non-small-cell lung cancer [9]</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">35248874798</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:indexed-name>Olaussen K.A.</ce:indexed-name>
<ce:surname>Olaussen</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Fouret P.</ce:indexed-name>
<ce:surname>Fouret</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Kroemer G.</ce:indexed-name>
<ce:surname>Kroemer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>New England Journal of Medicine</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss issue="15" volume="357"/>
<pagerange first="1559" last="1561"/>
</ref-volisspag>
<ref-website>
<ce:e-address type="url">http://content.nejm.org/cgi/reprint/357/15/1559.pdf</ce:e-address>
</ref-website>
<ref-text>DOI 10.1056/NEJMc072007</ref-text>
</ref-info>
<ref-fulltext>K.A. Olaussen, P. Fouret, and G. Kroemer ERCC1-specific immunostaining in non-small-cell lung cancer N Engl J Med 357 2007 1559 1561 (Pubitemid 47572656)</ref-fulltext>
</reference>
<reference id="35">
<ref-info>
<ref-title>
<ref-titletext>Validation of ERCC1-XPF immunodetection-letter</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77951718966</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:indexed-name>Olaussen K.A.</ce:indexed-name>
<ce:surname>Olaussen</ce:surname>
</author>
<author seq="2">
<ce:initials>J.C.</ce:initials>
<ce:indexed-name>Soria J.C.</ce:indexed-name>
<ce:surname>Soria</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="70"/>
<pagerange first="3851" last="3852"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>K.A. Olaussen, and J.C. Soria Validation of ERCC1-XPF immunodetection-letter Cancer Res 70 2010 3851 3852</ref-fulltext>
</reference>
</bibliography></tail></bibrecord></item></abstracts-retrieval-response>